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Abstract
Background: Vitamin D deficiency is implicated in neoplastic processes in multiple organs, including the pancreas.
While animal and human data have established a relationship between serum vitamin D (25(OH)D) and the
development of pancreatic cancer, few studies have examined the effects of 25(OH)D on time to progression (TTP)
and overall survival (OS) in this patient population. We hypothesize that lower baseline serum concentrations (BSC)
of 25(OH)D will be associated with decreased TTP and OS.
Methods: This retrospective analysis of 1222 patients with pancreatic cancer aims to identify potential relationships
between 25(OH)D and both TTP and OS, while controlling for the effects of ethnicity and body mass index (BMI).
Baseline 25(OH)D was divided into quartiles defined as deficient (<20 ng/mL), insufficient (20–39 ng/mL), sufficient
(40–59 ng/mL), and optimal (≥60 ng/ml). Statistical significance was declared if the two-sided p-value was ≤ 0.05.
Results: For the 627 subjects included for analysis, the median 25(OH)D was 27 ng/mL (range 4 to 114), 30.0 %
were 25(OH)D deficient (<20 ng/mL), and 47.2 % were insufficient (20–39 ng/mL). Ethnicity (p < 0.0001) and BMI
(p = 0.05) were significantly associated with (BSC)of 25(OH)D, while TTP (p = 0.39) and OS (p = 0.37) were not
associated.
Conclusion: Suboptimal vitamin D levels (<60 ng/mL) occurred in 96 % of patients analyzed. Both ethnicity and
BMI were statistically significantly associated with vitamin D deficiency and insufficiency. Similar to results previously
reported in the literature, this analysis did not identify a significant association between BSC of 25(OH)D and OS or
TTP in patients with pancreatic cancer.
Keywords: Body mass index, Pancreatic neoplasms, Vitamin D deficiency, Overall survival, Progression free
survival, Cancer
Background
Vitamin D is a steroid hormone primarily obtained
through the synthesis of 7-dehydrocholesterol following
sun exposure, and secondarily through dietary intake of
certain fish, fortified foods and beverages, and dietary
supplements. The optimal serum concentration of
25-hydroxyvitamin D (25(OH)D) varies among sources. A
widely accepted ideal level is 35–55 ng/mL, but other
sources site a broader range of 30–70 ng/mL as opti-
mal [1–3]. The National Health and Nutrition Exam-
ination Survey (2005 to 2006) identified a 41.6 %
prevalence of vitamin D deficiency (serum 25(OH)D
<20 ng/mL) in the United States [4]. Vitamin D levels are
affected by ethnicity, body mass index (BMI), geographic
exposure to sunlight, age, and disease [3]. Because of the
vast biological role of vitamin D, especially in mechanisms
commonly associated with cancer, understanding the ef-
fects of vitamin D deficiency on disease development and
progression is critical.
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Although the biologically active form of vitamin D is
1,25-hydroxyvitamin D (1,25(OH)2D), total circulating
vitamin D from dietary sources, supplements, and sun
exposure are best represented by 25(OH)D [5, 6]. Not
only is vitamin D responsible for regulating calcium and
phosphorous levels in the human body, but it also has
anti-proliferative and immunomodulatory effects via
autocrine and paracrine signaling [1]. As a lipid-soluble
molecule, it readily diffuses across plasma membranes.
By binding to the vitamin D receptor (VDR) on the nu-
cleus, it affects target genes involved in intracellular sig-
naling pathways including cell growth, differentiation,
adhesion, and apoptosis, making it of interest to study in
relation to cancer [5, 6]. Alteration of such cellular
mechanisms plays a critical role in cancer development
and suggests a potential relationship between vitamin D
and cancer.
While the relationship between serum 25(OH)D levels
and cancer opens a broad area for analysis, ample re-
search has been conducted analyzing vitamin D and risk
of cancer development in prostate, breast, and colorectal
cancers [3, 6–10]. Vitamin D supplements have been
shown to reduce the risk of cancer development by 77 %
when compared to and verified with placebos, and a
2006 study observed a 29 % reduction in cancer death
rate for every 10 ng/mL increase in vitamin D [11]. Simi-
larly, ambient exposure to ultraviolet light, especially
ultraviolet B-rays (UVB), has been shown to reduce the
risk of pancreatic cancer development [12–14]. Despite
the evidence supporting decreased risk of pancreatic
cancer in individuals with higher serum 25(OH)D, the
relationship between serum 25(OH)D and its effect on
pancreatic cancer progression has not been extensively
studied. Pancreatic cancer is the fourth leading cause of
cancer related death in the United States with a 6 % 5-
year survival rate, and 75 % mortality rate within the
first year of diagnosis [7, 15, 16]. Contradictory results
describing the relationship between vitamin D and pan-
creatic cancer make it difficult for researchers to draw
consistent conclusions [17, 18]. While multiple studies
suggest adequate 25(OH)D levels may decrease inci-
dence of pancreatic cancer, Stolzenberg et al. conducted
a pooled, nested, case–control study of eight cohorts,
finding that higher levels of vitamin D (>40 ng/mL) were
associated with a two-fold increase in risk of pancreatic
cancer development (OR = 2.12, 95 % CI: 1.23, 3.64)
[17]. Such results suggest vitamin D supplementation in
cancer patients should be monitored carefully.
Despite this data, in vitro and in vivo studies of pan-
creatic cancer cell lines found that 25(OH)D inhibited
cell line growth, while analogs of 25(OH)D inhibited
pancreatic cell proliferation, induced differentiation, pro-
moted apoptosis in vitro, and inhibited pancreatic tumor
growth in vivo [18–20]. A study published in May 2015
found that activation of vitamin D/VDR signaling led to
inhibition of FOXM1, a direct transcriptional target of
VDR, causing a suppression of tumor stemness, growth,
and metastasis [15]. These results imply vitamin D pos-
sesses anti-tumorigenic properties that may be useful in
preventing development or progression of cancer.
Although in vitro studies have identified vitamin D
and its receptor as potential targets for inhibiting pan-
creatic cancer development or progression, genetic stud-
ies to date have not identified an association between
the 25(OH)D, the VDR, and pancreatic cancer [21, 22].
In an analysis of 11 genes (213 single nucleotide poly-
morphisms) related to vitamin D synthesis, metabolism,
and signaling, no individual genes were significantly as-
sociated with pancreatic cancer [22].
The first study (CALGB 151006) to examine the rela-
tionship between serum 25(OH)D in patients with pan-
creatic cancer and time to progression (TTP) and overall
survival (OS) was a correlative study conducted in May
2014 [23]. These results did not support a statistically
significant relationship between 25(OH)D levels and
TTP or OS [23]. This current retrospective study aims
to contribute to the literature exploring the relationship
between vitamin D and TTP and OS in pancreatic can-
cer patients. It is hypothesized that lower baseline serum
concentrations (BSC) of 25(OH)D will be associated
with decreased TTP and OS.
Methods
Study population
Eligible participants included patients with pancreatic
cancer age 18 years or older, seen at any one of the five
Cancer Treatment Centers of America (CTCA) hospitals
between January 1, 2011, and April 30, 2014, who had
one or more recorded serum 25(OH)D blood draws.
Patients were excluded from the study if there was a
currently active second malignancy other than non-
melanomatous skin cancer or carcinoma in-situ of cer-
vix. Institutional Review Board (IRB) exemption was ob-
tained for this project. For each study participant, data
points collected included but were not limited to demo-
graphics, number of treatment regimens prior to presen-
tation at CTCA, stage of pancreatic cancer, and value of
each serum 25(OH)D draw.
Vitamin D and survival variables
Data were obtained from the institutional electronic
medical record system. Baseline serum concentration of
25(OH)D and all subsequent serum measurements were
divided into quartiles for analysis defined as deficient
(<20 ng/mL), insufficient (20–39 ng/mL), sufficient
(40–59 ng/mL), and optimal (≥60 ng/mL). Quartiles
were determined based on cutoffs used in literature
in addition to nutritionist and naturopathic physician
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recommendations from our facility for our patient
population [3, 11, 19, 24]. Measured as days from
diagnosis to progression of disease, TTP (defined as
change in treatment supported by objective evidence
of progression of disease or death in the absence of
documented disease progression) was recorded for
each patient. Overall survival, measured as days from
diagnosis to date of death, was also recorded for each
patient. The date of last patient contact was used to
represent TTP and/or OS for patients without docu-
mented progression, date of death, or for those pa-
tients still living. Statistical survival analyses censored
patients fitting these conditions.
Three variables known to influence serum levels of
25(OH)D include age, body mass index (BMI), and
ethnicity. This study did not evaluate the effect of age
on 25(OH)D, but did assess age at diagnosis. For this
study, BMI was divided into quartiles: underweight
(<18.5 kg/m2), healthy weight (18.5–24.9 kg/m2), over-
weight (25–29.9 kg/m2), and obese (≥30 kg/m2). Self-
reported ethnicity was recorded for each patient.
Statistical analysis
Statistical analyses were completed using the Statistical
Analysis System (SAS). The initial analysis for each pri-
mary variable, TTP and OS, compared the 25(OH)D
quartiles based on the use of Kaplan-Meier survival
curves and the Log Rank test. Additionally, the vitamin
D groups were compared after adjusting for important
covariates, including number of prior cancer therapies,
BMI, and ethnicity, using the Cox Proportional Hazard
model. Patients lost to follow-up, and, therefore lacking
a documented date of progression or death, were cen-
sored. Statistical significance was declared if the two-
sided p-value was ≤ 0.05.
Results
A total of 1222 patients with pancreatic cancer were
seen during the defined time period, of which 1017 pa-
tients had at least one had recorded serum concentra-
tion of 25(OH)D. Out of the 1017 patients who had
baseline vitamin D values, 627 had not received cancer
directed therapy prior to admission at CTCA. Because
prior treatment could affect nutritional status of a pa-
tient, only patients who had not received prior therapy
were included for analysis.
As summarized in Table 1, the majority of subjects
were Caucasian and had stage IV pancreatic cancer. The
average age at diagnosis was 57 (range: 31–82, SD:7.7).
Gender was equally represented, and the majority of the
samples were 25(OH)D insufficient. The patients who
had a BMI of 25 or higher (33 %) primarily fell into the
insufficient and deficient 25(OH)D quartiles. Even the
majority of patients with a healthy BMI had insufficient
BSC of 25(OH)D (48 %). Figure 1 depicts the frequency
of patients per baseline 25(OH)D quartile. Of the patient
characteristics analyzed, ethnicity (p < 0.0001) and BMI
(p = 0.05) were statistically significantly associated with
BSC of 25(OH)D.
Figure 2 depicts the average TTP per baseline
25(OH)D quartile. Kaplan-Meier survival analysis re-
sulted in no statistically significant association be-
tween TTP and BSC of 25(OH)D (p = 0.39, deficient
vs. insufficient quartiles HR = 1.1; 95 % CI = 0.9 to
1.5, deficient vs. sufficient quartiles HR = 1.1; 95 % CI
= 0.8 to 1.5, deficient vs. optimal quartiles HR = 0.7;
95 % CI = 0.4 to 1.3, insufficient vs. sufficient quartiles
HR = 0.9; 95 % CI = 0.7 to 1.3, insufficient vs. optimal
quartiles HR = 0.6; 95 % CI = 0.4 to 1.1, sufficient vs.
optimal quartiles HR = 0.7; 95 % CI = 0.4 to 1.2). For
the progression analysis, 317 observations (52 %) were
censored given that a documented date of disease
progression or death was not available. Other vari-
ables of interest analyzed using a Type III ANOVA
test, including ethnicity (p = 0.35, HR = 1.2; 95 % CI =
0.9 to 1.70) and BMI (p = 0.70, HR = 1.0; 95 % CI =
0.98 to 1.0), were not statistically significantly associ-
ated with TTP.
At the time of data collection, 480 (76 %) of the study
participants had expired. Statistical analysis of average
OS per baseline 25(OH)D quartile, depicted in Figure 3,
did not result in a significant relationship between the
two variables (p = 0.37, deficient vs. insufficient quartiles
HR = 1.0; 95 % CI = 0.8 to 1.2, deficient vs. sufficient
quartiles HR = 1.0; 95 % CI = 0.8 to 1.4, deficient vs. opti-
mal quartiles HR = 1.6; 95 % CI = 0.9 to 2.7, insufficient
vs. sufficient quartiles HR = 1.1; 95 % CI = 0.8 to 1.3, in-
sufficient vs. optimal quartiles HR = 1.6; 95 % CI = 0.9 to
2.7, sufficient vs. optimal quartiles HR = 1.5; 95 %
CI = 0.9 to 2.6). For the overall the survival analysis,
143 observations (23 %) were censored given that a
documented date of death was not provided. A
Type III ANOVA revealed that ethnicity (p = 0.79,
HR = 1.1; 95 % CI = 0.8 to 1.4) and baseline BMI (p = 0.84,
HR = 1.0; 95 % CI = 0.98 to 1.0) were not statistically sig-
nificantly associated with OS.
Thus, the statistical results of this study showed
both ethnicity and BMI impact BSC of 25(OH)D,
and there is no statistically significant relationship
between BSC of 25(OH)D and TTP or OS.
Discussion
This analysis is one of the first to analyze the association
between BSC of 25(OH)D and both TTP and OS in pa-
tients with pancreatic cancer. The results of this study
showed that BSC of 25(OH)D is not statistically signifi-
cantly associated with either TTP or OS. Therefore, BSC of
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25(OH)D does not appear to be indicative of prognosis in
pancreatic cancer patients.
Despite literature noting the protective properties of
25(OH)D and cancer development, the current data does
not support an association between BSC of 25(OH)D and
disease progression in patients with pancreatic cancer.
Although graphical depiction suggests optimal BSC of
25(OH)D is associated with greatest OS, the same quartile
experiences the most rapid TTP. Further research specif-
ically aimed at understanding the role of 25(OH)D during
the course of disease in pancreatic cancer, is needed to
identify the presence or absence of such protective proper-
ties against disease progression.
In a recent correlative randomized trial, serum 25(OH)D
of 256 pancreatic cancer patients was analyzed for associa-
tions with TTP and OS. Similar to our findings, the results
showed no significant association between 25(OH)D and
either variable (TTP p = 0.6, OS p = 0.95). However, that
study did identify a statistically significant relationship be-
tween ethnicity and 25(OH)D, placing emphasis on the pri-
mary endogenous metabolism of vitamin D following
absorption by the skin [19]. Because darker skin pigments
absorb less UV light from the sun, darker-skinned individ-
uals will likely have lower serum concentration of vitamin
D than lighter-skinned individuals. Similar to existing litera-
ture, our study identified a statistically significant relation-
ship between ethnicity and BSC of 25(OH)D (p < 0.0001).
Fig. 1 Distribution of baseline 25(OH)D levels among pancreatic
cancer patients(n = 627). ng/mL: nanogram per milliliter
Table 1 Distribution of Demographics Grouped by 25(OH)D Quartile
Vitamin D Quartile
<20 ng/mL 20–39 ng/mL 40–59 ng/mL 60 + ng/mL Total 25(OH)D
Characteristic No. patients (%) No. patients (%) No. patients (%) No. patients (%) No. patients (%) Avg. ng/mL (SD) P-value
Gender
Male 105 (56) 167 (56) 63 (52) 7 (32) 342 (55) 28 (±14) 0.15
Female 83 (44) 129 (44) 58 (48) 15 (68) 285 (45) 30 (±17)
Ethnicity <0.0001
Caucasian 118 (25) 236 (50) 106 (22) 16 (3) 476 (76) 31 (±15)
African American 57 (53) 36 (34) 11 (10) 3 (3) 107 (17) 22 (±15)
Hispanic 0 (0) 7 (44) 0 (0) 1 (6) 16 (3) 22 (±14)
Asian 0 (0) 4 (100) 0 (0) 0 (0) 4 (0.6) 30 (±6)
Polynesian 0 (0) 0 (0) 1 (100) 0 (0) 1 (0.2) 48 (±0)
Other* 5 (22) 5 (22) 3 (13) 2 (9) 23 (4) 30 (±16)
Cancer Stage 0.36
1B 4 (50) 2 (25) 2 (25) 0 (0) 8 (1) 23 (±14)
2A 13 (48) 9 (33) 4 (4) 1 (4) 27 (4) 24 (±16)
2B 15 (31) 27 (56) 3 (6) 3 (6) 48 (8) 27 (±14)
3 24 (28) 40 (47) 19 (22) 3 (3) 86 (14) 30 (±15)
4 131(29) 216 (48) 92 (20) 15 (3) 454 (72) 29 (±16)
Non-staged 1 (25) 2 (50) 1 (25) 0 (0) 4 (1) 28 (±11)
BMI (kg/m2) 0.05
< 18.5 7 (27) 8 (31) 9 (35) 2 (8) 26 (4) 35 (±19)
18.5–24.9 67 (25) 126 (48) 57 (22) 14 (5) 264 (42) 31 (±17)
25–29.9 74 (36) 98 (47) 33 (16) 2 (1) 207 (33) 26 (±13)
30+ 40 (31) 64 (49) 22 (17) 4 (3) 130 (21) 28 (±14)
*Other ethnicities are patients who did not identify with any ethnicity listed above
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Body Mass Index (BMI) is another factor cited in the
literature as having an inverse influence on serum vita-
min D [25]. Our study demonstrated a statistically sig-
nificant relationship between BMI and BSC of vitamin
D (p=0.05). In a study evaluating serum concentration of
25(OH)D in healthy individuals compared to obese
individuals, researchers found that 25(OH)D was in-
versely correlated with BMI (p = 0.007) [26]. While basal
rates of serum 25(OH)D did not differ immediately post
radiation, a statistically significant difference emerged
between obese and healthy individuals 24 h after
exposure. Similarly, there was a significant association
Fig. 2 Kaplan-Meier survival curve depicting the association between baseline 25(OH)D quartile and time to disease progression (p=0.39)
Fig. 3 Kaplan-Meier survival curve depicting the association between baseline 25(OH)D quartile and overall survival in pancreatic
cancer patients (p=0.37)
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between BMI and peak 25(OH)D levels in an oral
challenge [26]. Our study only observed 25(OH)D
and BMI at baseline, a limitation that may have pre-
vented identifying a dynamic association between
changes in BMI with changes in 25(OH)D over time.
Since subcutaneous fat is a deposition site for vitamin
D, overweight and obese individuals may sequester
vitamin D from the blood and store it in a non-
readily available form, causing a prevalence of vitamin
D deficiency among individuals with increased BMIs
[23]. The association between BMI and 25(OH)D
identified in the current study indicates an important
area for future research.
The strength of the current study lies in the large sam-
ple size included for analysis; however, the design was
retrospective in nature. Although it provides insight into
possible associations between vitamin D and pancreatic
cancer, a prospective study is subject to less bias and
possible confounders. The retrospective nature of the
study limits the ability to account for initiation of and
compliance to vitamin D supplementation. Some pa-
tients expired prior to documentation of progression
of disease. For these patients, date of expiration was
used for both OS and TTP as death was considered
disease progression. Given our patient population
travels from many states across the country, as well
as internationally, it was not feasible to assess the
season during which blood was drawn (and, therefore
relative sun exposure) to determine potential effects
on serum25(OH)D.
Our analysis suggests that vitamin D is not signifi-
cantly associated with rates of disease progression or
overall survival in an advanced pancreatic cancer
population; however, the limitations of a retrospective
and the inconclusive reports of this topic in the lit-
erature suggest more prospective trials are needed to
further define potential associations between vitamin
D and pancreatic cancer progression. The most recent
literature evaluating the effect of vitamin D on
gastrointestinal disease, including pancreatic cancer,
continues to identify the inconsistencies and contra-
dictions of published findings, as well as the need for
a prospective human interventional trial [27]. Further-
more, research is moving towards analysis of vitamin
D analogs and their potential to activate the desirable
anti-inflammatory, immunomodulatory, and apoptotic
effects while avoiding the homeostatic effects on cal-
cium and phosphorous levels. Analogs have also been
cited to synergistically enhance the desired effects of
chemotherapy when used in combination [28, 29]. Fu-
ture research should prospectively document the vari-
ables assessed in this current study to best define
associations between BSC of 25(OH)D and OS and
TTP.
Conclusion
This study did not identify a significant association
between 25(OH)D and overall survival or time to pro-
gression in patients with pancreatic cancer. Future
prospective studies should explore potential relation-
ships between 25(OH)D and OS and TTP in pancre-
atic cancer. Additional studies may also apply analysis
to changes in serum 25(OH)D in association with
changes in other variables, such as BMI.
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